Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

While reverse mergers offer a faster route to public markets, they bypass the extensive investor meetings of a traditional IPO. This can result in a narrowly held story and weaker sell-side coverage, forcing companies to spend 6-12 months post-deal building the investor base they missed.

An improving IPO market doesn't cannibalize M&A activity but rather provides private companies with a dual-track option. Barclays advises clients to evaluate both public market and M&A paths simultaneously, treating them as complementary strategies for value creation, not mutually exclusive choices.

Albareo was ready to IPO with strong investor interest in summer 2015, but the market window slammed shut due to external events like the Martin Shkreli scandal. This forced the company into a creative reverse merger, a stark reminder that IPO timing is ultimately dictated by market sentiment beyond a company's control.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

Biotech firms are increasingly using reverse mergers paired with substantial PIPE financings ($200M+) as an alternative path to the public markets. This "IPO-esque" strategy offers speed and efficiency but may trade off the broader investor exposure gained through a traditional, lengthy roadshow process.

To tap into public market investors, Adaptin Bio merged with a 'Form 10' public shell company. This distinct route is not a SPAC as it doesn't raise money in an IPO. Instead, it provides a faster path to becoming a public reporting entity to attract a wider investor base.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.

The closed IPO window forced many private biotech companies to achieve significant clinical milestones, like Phase 2 proof-of-concept, while still private. This has created an unusual cohort of well-seasoned, de-risked companies with attractive valuations, poised to be highly appealing to public investors.